A study to describe the one-year persistence in participants treated by Flixabi (infliximab) or Imraldi (Adalimumab) as prescribed by the physician for each of the 5 following indications: Rheumatoid Arthritis (RA), Ankylosing Spondylitis (AS), Psoriatic Arthritis (PsA), Crohn's Disease (CD) [adults and children] and Ulcerative Colitis (UC) [adults for both treatments and children only for Flixabi].

Inclusion/ Exclusion Criteria

Key Inclusion Criteria:

• Adult participant (18 years and over)

  • treated for one of the following conditions: RA, AS, PsA, CD, UC.
  • either active substance naïve or treated with the originator or another biosimilar at baseline.
  • for whom the treating physician has decided to treat by (naïve) or switch from originator or another biosimilar to Flixabi or Imraldi.
  • participants who had initiated Flixabi or Imraldi at most 12 months before the baseline will also be included in the cohort.

• Paediatric participants (6-17 years):

  • treated for one of the following conditions: CD, UC.
  • either active substance naïve or treated with another biosimilar at baseline.
  • for whom the treating physician has decided to treat by (naïve) or switch to Flixabi (for both indications) or Imraldi (only for Crohn's disease).
  • participants who had initiated Flixabi or Imraldi at most 12 months before the baseline will also be included in the cohort.

Key Exclusion Criteria:

• Participant treated for psoriasis.
• Participant who are not to be followed up in the same investigator site for 2 years after baseline.

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

Participants either infliximab naïve or switched from Remicade or CT-P13 to Flixabi who are treated with Flixabi, and either adalimumab naïve or switched from Humira or other adalimumab biosimilars to Imraldi who are treated with Imraldi, for RA, AS, PsA, CD, and UC as prescribed by the physician in clinical practice.